Table 1.
Summary of neural crest and mesenchymal lineage marker expression.
| Fraction | NCC | NCC | MSC | MSC | MSC | MSC | MSC |
|---|---|---|---|---|---|---|---|
| CD49d | CD57 | CD29 | CD73 | CD105 | CD140a | CD146 | |
| LNGFR(+)THY-1(+) | 31.7 ± 1.5% | 69.6 ± 1.1% | 88.2 ± 2.3% | 26.1 ± 1.3% | 16.4 ± 1.2% | 8.6 ± 0.5% | 37.4 ± 2.6% |
| LNGFR(+)THY-1(−) | 3.3 ± 2.4% | 60.5 ± 6.0% | 44.4 ± 7.1% | 0.4 ± 0.4% | 0.2 ± 0.2% | 0.0 ± 0.0% | 2.5 ± 2.5% |
| LNGFR(−)THY-1(+) | 10.1 ± 1.2% | 40.3 ± 1.5% | 62.1 ± 4.5% | 9.6 ± 0.6% | 5.7 ± 1.2% | 1.7 ± 0.2% | 15.3 ± 1.6% |
| LNGFR(−)THY-1(−) | 0.8 ± 0.2% | 40.8 ± 3.4% | 14.0 ± 1.1% | 0.4 ± 0.1% | 0.4 ± 0.1% | 0.1 ± 0.0% | 0.7 ± 0.2% |
The proportion of the NCC markers (CD49d and CD57) and MSC markers (CD29, CD73, CD105, CD140a, and CD146) in the LNGFR/THY-1 double positive, single-positive and double-negative fractions were evaluated by FACS analysis (related to Fig. 1 and Supplementary Figure 2). The expression level for NCC/MSC markers was the highest in LNGFR(+)THY-1(+) fraction compared to that in other single positive and double negative fraction.